Rezolute announces positive Phase 3 upLIFT results in tumor hyperinsulinism
FROM THE WIRE · MANILATIMES.NET
Primary efficacy endpoint achieved based on preliminary results from a November 5th data evaluation
Read at the source ↗MARKET IMPACTNEUTRAL✦ News Impact agent estimateTone: expected bullishMeeting the primary endpoint in Phase 3 is a positive catalyst for the company.AI-generated summary
✦ IN BRIEF · AIAI-generated summary
- 01The Phase 3 upLIFT study achieved its primary efficacy endpoint.
- 02The results are based on preliminary data from a November 5th evaluation.
- 03The study concerns tumor hyperinsulinism.
NEWS IMPACT AND MARKET REACTIONChange since the story · reference
Impact and summary are estimates by the News Impact AI agent, not financial advice.Open in Markets